← Evidence library

BIB_385

Adjuvant combination checkpoint intensification DOES NOT IMPROVE outcomes over anti-PD-1 monotherapy in resected melanoma — two major negative Phase 3 trials: (1) RELATIVITY-098 (Ascierto PA, Schadendorf D, Long GV et al., Nat Med 2025, PMID 41109920): nivolumab + relatlimab [anti-LAG-3] vs nivolumab alone, Stage III/IV, n=1,093 — RFS HR 1.01 (95% CI 0.83–1.22; P=0.928); grade 3/4 TRAEs 19% vs 8%; (2) KEYVIBE-010 (Lancet Oncol February 2026, DOI 10.1016/S1470-2045(25)00709-0): vibostolimab [anti-TIGIT] + pembrolizumab vs pembrolizumab alone, Stage IIB–IV, n=1,402 — RFS HR 1.25 (95% CI 0.9–1.8)…

Evidence grade

A

Tier

1 (RELATIVITY-098 — Nature Medicine Tier 1 journal; Phase 3 RCT n=1,093; double-

Cited by tasks

17, 18, 19a

Identifiers

PMC12705465 · DOI:10.1016/S1470-2045(25 · PMID:41109920

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_385/findings.md (research corpus). This page is a short context summary — not individualised medical advice.